source
- Novartis weighs private-pay launches in Europe as MFN rules pressure government pricingNovartis CEO Vas Narasimhan said the company is exploring the option of introducing new medicines directly to private or self‑pay patients in Europe. The discussion is driven by the European Union…
- Artiva Biotherapeutics cuts 94% of workforce after patient deaths and failed autoimmune cell therapyArtiva Biotherapeutics announced it is halting development of its AlloNK natural killer cell therapy for autoimmune diseases and is laying off roughly 94% of its employees. The AlloNK product, an…